Altamira Therapeutics Ltd
NASDAQ:CYTO
Intrinsic Value
Altamira Therapeutics Ltd. engages in the development of novel products that address unmet medical needs in neurology and central nervous system disorders. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of CYTO.
CYTO's market price has consistently been higher than its intrinsic value.This persistent overvaluation suggests the market may be overly optimistic about
CYTO or that its price is influenced by factors unrelated to fundamentals.
Altamira Therapeutics Ltd's market capitalization is 3.1m USD.
CYTO stock price is 1.69 USD.
CYTO.
CYTO. Open DCF Valuation
CYTO. Open Relative Valuation
CYTO.
CYTO's short-term assets (1m CHF) exceed its short-term liabilties (889k CHF).
CYTO's ROE (Return on Equity) has significantly increased in the last 3 years from -72% to 418%.
CYTO's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from -67% to -148%, and is approaching profitability.
CYTO has negative Operating Income for the last twelve months.
CYTO has negative Net Income for the last twelve months.
CYTO's ROE (Return on Equity) for the past 12 months is very high and is equal to 418%.
CYTO's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -148%.
CYTO has negative Free Cash Flow for the last twelve months.
CYTO has negative three-year average ROE (Return on Equity): -315%. The company is not efficient at transforming stockholders' equity into net income.
CYTO has negative three-year average ROIC (Return on Invested Capital): -144%. The company is not efficient at using invested capital to generate operating income.
CYTO's long-term assets (8m CHF) exceed its long-term liabilties (1m CHF).
CYTO's D/E (Debt to Equity) is very low and is equal to 0.
CYTO's Altman Z-Score is very low and is equal to -2.76.
CYTO doesn't generate enough operating income (-6m CHF) to safely cover interest payments on its debt (148k CHF).
Fundamental Analysis
Altamira Therapeutics Ltd
Balance Sheet Decomposition
Altamira Therapeutics Ltd
| Current Assets | 1.2m |
| Cash & Short-Term Investments | 617.4k |
| Receivables | 74.8k |
| Other Current Assets | 530.9k |
| Non-Current Assets | 6.5m |
| Long-Term Investments | 2.5m |
| PP&E | 80.1k |
| Intangibles | 3.9m |
| Other Non-Current Assets | 10 |
| Current Liabilities | 888.9k |
| Accounts Payable | 440.4k |
| Accrued Liabilities | 448.5k |
| Non-Current Liabilities | 346.6k |
| Other Non-Current Liabilities | 346.6k |
Earnings Waterfall
Altamira Therapeutics Ltd
|
Revenue
|
0
CHF
|
|
Operating Expenses
|
-5.9m
CHF
|
|
Operating Income
|
-5.9m
CHF
|
|
Other Expenses
|
2m
CHF
|
|
Net Income
|
-3.9m
CHF
|
Free Cash Flow Analysis
Altamira Therapeutics Ltd
CYTO Profitability Score
Profitability Due Diligence
Altamira Therapeutics Ltd's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
Score
Altamira Therapeutics Ltd's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
CYTO Solvency Score
Solvency Due Diligence
Altamira Therapeutics Ltd's solvency score is 43/100. The higher the solvency score, the more solvent the company is.
Score
Altamira Therapeutics Ltd's solvency score is 43/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CYTO Price Targets Summary
Altamira Therapeutics Ltd
Shareholder Return
CYTO Price
Altamira Therapeutics Ltd
| Average Annual Return | -30.73% |
| Standard Deviation of Annual Returns | 68.73% |
| Max Drawdown | -100% |
| Market Capitalization | 3.1m USD |
| Shares Outstanding | 1 837 840 |
| Percentage of Shares Shorted | 24.2% |
Company Profile
Altamira Therapeutics Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Altamira Therapeutics Ltd. engages in the development of novel products that address unmet medical needs in neurology and central nervous system disorders.
You don't have any saved screeners yet
